| Trial Identifier: | D8220R00031 |
| Sponsor: | AstraZeneca |
| NCTID: | NCT04964908 |
| Start Date: | December 2021 |
| Primary Completion Date: | March 2023 |
| Study Completion Date: | March 2023 |
| Condition: | CLL (Chronic Lymphocytic Leukemia) |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
| Country | Location |
|---|---|
| Kuwait | Kuwait, Kuwait |
| Turkey | Adana, Turkey |
| Turkey | Ankara, Turkey |
| Turkey | Ankara, Turkey |
| Turkey | Izmir, Turkey |
| Turkey | Izmir, Turkey |
| Turkey | Samsun, Turkey |
| India | Ahmedabad, India |
| India | Bangalore, India |
| India | Bangalore, India |
| India | Faridabad, India |
| India | Hitech, India |
| India | New Delhi, India |
| India | New Delhi, India |
| India | Shibpur, India |
| Saudi Arabia | Jeddah, Saudi Arabia |
| Saudi Arabia | Riyadh, Saudi Arabia |
| Egypt | Cairo, Egypt |
| Egypt | Cairo, Egypt |
| Argentina | Argentina, Argentina |
| Dominican Republic | Dominican Republic, Dominican Republic |
| Colombia | Colombia, Colombia |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2023 Pharma Intelligence UK Limited (Citeline), a Norstella company